Drug Option For Patients Beginning HIV Treatment Studied

email to a friend

printer friendly

opinions

Current Article Ratings:

Patient / Public:
Healthcare Prof:
Article Opinions:	1 posts

HIV integrase inhibitor raltegravir "is safe and effective for patients beginning treatment against HIV, according to researchers who completed a two-year, multi-site Phase III clinical trial comparing it with standard antiretroviral drugs," the Atlanta Business Journal reports (Karkaria, 8/10). The study - to be published in an upcoming issue of the Lancet - was led by Jeffrey Lennox, a professor of medicine (infectious diseases) at Emory University School of Medicine, chief of Emory's HIV/AIDS clinical trials unit and vice-chair of medicine at Grady Memorial Hospital (Emory University's Robert W. Woodruff Health Sciences Center release, 8/3). Researchers also found that raltegravir, "is overall as effective as efavirenz, a reverse transcriptase inhibitor," and "also had faster onset of action and fewer adverse side effects," according to the Business Journal. Lennox said, "These results provide an additional potent, well-tolerated treatment option for newly diagnosed patients with HIV infection" (8/10).

This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org.

© Henry J. Kaiser Family Foundation. All rights reserved.

• Additional
• References
• Citations